Welcome to our dedicated page for PLUS THERAPEUTICS news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on PLUS THERAPEUTICS stock.
Plus Therapeutics, Inc. (symbol: PSTV) is a cutting-edge clinical-stage pharmaceutical company based in Austin, Texas. Founded in 1996 and initially known as Cytori Therapeutics, Inc., the company rebranded to Plus Therapeutics in July 2019 to better reflect its mission and evolving focus. Specializing in the discovery, development, and manufacture of innovative treatments for cancer and other debilitating diseases, Plus Therapeutics aims to bring new hope to patients through cutting-edge medical solutions.
The company's lead product candidate is DocePLUS, a protein-stabilized, pegylated liposomal formulation of docetaxel specifically designed for the treatment of small cell lung cancer. Additionally, Plus Therapeutics is developing DoxoPLUS, a generic pegylated liposomal encapsulated doxorubicin aimed at treating breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma.
In a significant partnership, Plus Therapeutics has entered into a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. This collaboration aims to propel the company further into the forefront of cancer treatment research.
One of the company's groundbreaking developments is the novel injectable radiotherapy called Rhenium (186Re) obisbemeda. This treatment is specifically formulated to deliver targeted high-dose radiation in Central Nervous System (CNS) tumors, optimizing patient outcomes while minimizing off-target risks. The product's efficacy and safety are being evaluated for recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. These trials are supported by grants from the National Cancer Institute (NCI) and the Cancer Prevention & Research Institute of Texas (CPRIT), totaling millions in funding.
Financially, Plus Therapeutics recently secured $6.5 million in upfront gross proceeds, with the potential to receive up to an additional $11.5 million through potential warrant exercise, amounting to approximately $18 million in total gross proceeds. These funds will be essential in advancing the company’s robust pipeline and bringing innovative treatments to market.
Investors and stakeholders can stay informed of the latest developments and financial updates by reaching out to key contacts such as Corey Davis, Ph.D. of LifeSci Advisors, and Charles Y. Huang, MBA, Director of Capital Markets and Investor Relations.
Plus Therapeutics (Nasdaq: PSTV) announced that Marc H. Hedrick, M.D., President and CEO, will present at the Benzinga Healthcare Small Cap Conference on September 30, 2021, at 4:20 p.m. ET. The presentation will provide an overview of the company's innovative, targeted radiotherapeutics aimed at rare cancers. Attendees can register for the presentation and one-on-one meetings through the Benzinga website. A replay will be available on Plus Therapeutics' Investor Relations page. The company is focused on developing nanoliposome-encapsulated drugs to enhance safety and efficacy for patients.
Plus Therapeutics, Inc. (Nasdaq: PSTV) will present data on its investigational Rhenium-186 NanoLiposome (186RNL) for treating recurrent glioblastoma at the ASTRO 2021 Annual Meeting, scheduled for October 24-27 in Chicago. The presentation, titled "Image-guided Rhenium-186 NanoLiposome brachytherapy in the treatment of recurrent glioblastoma," will occur on October 27 at 1:00 p.m. CT. The abstract will be available online on October 22, and the poster will be accessible on the Company’s website. Plus Therapeutics focuses on targeted radiotherapeutics for rare cancers.
Plus Therapeutics (PSTV) announced the appointment of Dr. Norman LaFrance as Chief Medical Officer and Senior Vice President, effective December 8, 2021. Dr. LaFrance brings nearly 40 years of experience in nuclear medicine and pharmaceuticals, with expertise in radiotherapeutics and drug development. His previous roles include Chief Medical Officer at Jubilant Pharma and Global Chief Medical Officer at IBA Molecular. CEO Marc Hedrick expressed confidence that Dr. LaFrance's extensive background will enhance the company's pipeline and support its long-term goals in addressing unmet medical needs in cancer treatment.
Plus Therapeutics (Nasdaq: PSTV) announced that its CEO, Marc H. Hedrick M.D., will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13 to 15, 2021. This virtual event offers investors a chance to engage with the company's management. A webcast of the presentation will be available on-demand starting September 13, 2021, at 7:00 a.m. on the company's website. Plus Therapeutics focuses on developing innovative radiotherapeutics targeting rare cancers using a unique nanotechnology platform.
Plus Therapeutics (PSTV) has partnered with RadioMedix for the commercial production of Rhenium-186 NanoLiposome (186RNL), a targeted radiotherapeutic for recurrent glioblastoma. This strategic alliance aims to ensure cGMP compliance, facilitating clinical studies slated for mid-2022. 186RNL is designed to effectively deliver radiation to central nervous system tumors. Plus Therapeutics is currently conducting a Phase 1 clinical trial for recurrent GBM, leveraging NIH support.
Plus Therapeutics has reported promising data from its ReSPECT™ Phase 1 trial for Rhenium-186 NanoLiposome (186RNL) in treating recurrent glioblastoma. The investigational drug demonstrated good tolerance at high radiation doses, outperforming standard therapies. Key findings include a mean dose of 392 Gy delivered safely, with no serious adverse events noted. The company plans to expand research into pediatric brain tumors, starting a Phase 1 study by mid-2022. The overall response rate will be a primary endpoint in the upcoming trials.
Plus Therapeutics (PSTV) recently presented promising preclinical data supporting its FDA IND application for Rhenium-186 Nanoliposome (186RNL) targeted radiotherapy aimed at treating leptomeningeal metastases (LM). The data, showcased at the Society for Neuro-Oncology's conference, indicated minimal toxicity and significant efficacy in animal models. Plans for a Phase 1 dose escalation clinical trial with patient accrual expected in Q4 2021 were also outlined. The trial will evaluate the treatment's safety and efficacy in patients previously treated for breast or non-small cell lung cancer with LM.
Plus Therapeutics, Inc. (Nasdaq: PSTV) announced it will present data on Rhenium-186 NanoLiposome from its Phase 1 ReSPECT™ trial for recurrent glioblastoma at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting, held virtually from August 21-25, 2021. The presentation titled "A two-part, Phase 1 study of Rhenium-186 NanoLiposome" will be made available on-demand beginning August 21. Lead presenter Michael G. DeCuypere, MD, PhD, will provide insights on the study's findings, which aim to enhance treatment for rare cancers.
AUSTIN, Texas, Aug. 11, 2021 – Plus Therapeutics (Nasdaq: PSTV) announced data presentation at the Third Annual Conference on Brain Metastases by the Society for Neuro-Oncology. The studies evaluate Rhenium-186 Nanoliposome (186RNL) for leptomeningeal metastases treatment. Andrew J. Brenner, M.D., will present findings from the ongoing ReSPECT-GBM Phase 1 trial and a preclinical study showing that 186RNL is well tolerated and improves survival in animal models. The conference runs from August 19-20, 2021, with data available to attendees.
Plus Therapeutics (PSTV) announced that CEO Marc H. Hedrick M.D. will provide a company overview at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 4:30 p.m. ET. The presentation will focus on Plus Therapeutics' innovative radiotherapeutics targeting rare cancers, utilizing a unique nanotechnology platform. Investors wishing to schedule meetings can contact the conference coordinator. A webcast will be available in the Investor Relations section of the Plus Therapeutics website.
FAQ
What is the current stock price of PLUS THERAPEUTICS (PSTV)?
What is the market cap of PLUS THERAPEUTICS (PSTV)?
What is Plus Therapeutics, Inc.?
What are the main products of Plus Therapeutics?
What is Rhenium (186Re) obisbemeda?
What partnerships does Plus Therapeutics have?
What recent financial achievements has Plus Therapeutics made?
Where is Plus Therapeutics headquartered?
What clinical trials is Plus Therapeutics involved in?
Who can investors contact for more information?
What was the former name of Plus Therapeutics?
When was Plus Therapeutics founded?
